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Overlapping fragments of the bovine herpesvirus-1 (BHV-1) glycoprotein (gD) ORF were expressed as trpE-gD fusion 
proteins in Escherichia coil to map linear neutralizing epitopes defined by BHV-l-specific MAbs. The MAbs 3402 and R54 
reacted with the expressed fragments on Western blots that located the epitopes between the amino acids 52-126 and 
165-216, respectively, of gD. Bovine covalescent sera with high neutralizing antibody titers against BHV-1 reacted with 
these bacterially expressed proteins containing both of the epitopes. Alignment of these sequences from BHV-1 with the 
corresponding region of the BHV-5 gD ORF sequences (reported here) identified several amino acid mismatches. Since the 
MAbs 3402 and R64 neutralize the BHV-1 and not BHV-5, it was presumed that these were important amino acids in defining 
the epitope. To further localize the neutralizing epitopes, synthetic peptides corresponding to these regions in the BHV-1 
gD ORF were tested for their capacity to block monoclonal antibody neutralization of BHV-1 infectivity. The peptides 
encompassing amino acids 92-106 (3402 epitope) and amino acids 202-213 (R54 epitope) of the BHV-1 gD competed with 
BHV-1 for the binding by MAbs 3402 and R54, respectively, in a dose-dependent manner. Antisera produced in rabbits to 
these peptides conjugated to a carrier reacted strongly with a 30-kDa protein by Western blotting and had neutralizing 
antibody titers against BHV-1. © 1995 Academic Press, Inc. 
INTRODUCTION 
Bovine herpesvirus-1 (BHV-1) causes conjunctivitis, 
respiratory and genital infections, and occasionally abor- 
tion and enteritis in cattle (Gibbs and Rweyemamu, 1977; 
Ludwig, 1983). BHV-1 strains fall into two different groups 
based on their DNA restriction profiles and pathogenic 
properties, the respiratory/abortogenic group (IBR, infec- 
tious bovine rhinotracheitis virus) and the nonaborto- 
genic genital group (IPV, infectious pustular vulvovagini- 
tis). The neurovirulent bovine herpesvirus (previously 
classified as BHV-1.3) has been reclassified recently as 
BHV-5 (Roizman et aL, 1992) and is known to cause epi- 
demics of a uniformly fatal encephalitis in calves (Carillo 
etaL, 1983a,b; French, 1962; Eugster etaL, 1974; Bartha 
et aL, 1969). The BHV-1 and BHV-5 virus strains share 
85% DNA homology, based on cross-hybridization of en- 
tire genomic DNA. However, the DNA restriction maps 
of BHV-1 and BHV-5 are distinct (Engles et aL, 1987; 
Bulach and Studdert, 1990), suggesting that differences 
exist in the nucleotide sequences of these virus strains 
throughout he genome. Previous reports (Metzler et al., 
1985, 1986; Friedli and Metzler, 1987; Collins eta/., 1993) 
also have demonstrated that genomic differences be- 
tween these two viruses are reflected in the antigenic 
properties including the major viral glycoproteins. The 
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envelopes of alpha herpesviruses, including herpes sim- 
plex viruses (HSV-1 and HSV-2), pseudorabies virus 
(PRV), and BHV-1, contain a number of functionally and 
structurally homologous glycoproteins. Herpesvirus gly- 
coproteins are important for the interaction of the virus 
with its host. The glycoproteins mediate infection of tar- 
get cells and, thus, influence cell and tissue tropism and 
are also major antigens recognized by the infected host's 
immune system (Little etaL, 1981; Highlander etaL, 1987; 
Johnson and Ligas, 1988; Glorioso eta/., 1984; Lupton 
and Reed, 1980). Three major glycoproteins, gB (gl), gO 
(gill), and gD (glV), have been identified on the virus 
envelope and the plasma membranes of BHV-l-infected 
cells (Marshall eta/., 1986; van Drunen Little-van den 
Hurk et al., 1984; van Drunen Little-van den Hurk and 
Babiuk, 1986) and are recognized by sera from BHV-1- 
infected cattle (Collins et al., t984; van Drunen Little-van 
den Hurk et aL, 1986). Immunization with affinity-purified 
gB, gO, and gD individually or in combination induces 
protective immune response against BHV-1 infection 
(Babiuk eta/., 1987; van Drunen Little-van den Hurk et 
al., 1990a). However, gB and gD are the only glycopro- 
teins that can induce immunity resulting in significant 
reductions in viral replication and shedding (Israel et 
al., 1992; van Drunen Little-van den Hurk et al., 1993). 
Glycoprotein D also induces a stronger and more consis- 
tent cellular immune response to BHV-1 than gB and gO 
(Hutchings et al., 1990). Monoclonal antibodies (MAbs) 
to gD show the highest complement-independent virus- 
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neutralizing activity and inhibit virus adsorption and pen- 
etration (Hughes et al., 1988; van Drunen Little-van den 
Murk eta/., 1990b; Dubuisson etaL, 1992). Herpes sim- 
plex virus glycoprotein gD is also involved in the patho- 
genesis of neurological disease (Izumi and Stevens, 
1990). These functional attributes of gD make it one 
of the most important proteins involved in immunity to 
BHV-1. 
The BHV-1 gD ORF codes for 417 amino acid (aa) 
residues and a protein with a molecular weight of 75K 
(Tikoo et al., 1990). Competitive binding assays using 
gD-specific MAbs have been used to map BHV-1 gD 
epitopes. Five epitopes, three interrelated and two inde- 
pendent, were reported as targets of neutralizing anti- 
bodies (Marshall et aL, 1988). Four antigenic domains 
have also been described by other investigators (Hughes 
eta/,, 1988; van Drunen Little-van den Hurk etaL, 1990b). 
A recent study using truncated and deleted gD-recombi- 
nant vaccinia virus proteins located these antigenic de- 
terminants on regions of the gD ORF (Tikoo et aL, 1993). 
In the present study, the coding sequences of two 
BHV-1 gD-specific epitopes recognized by neutralizing 
MAbs were mapped precisely by expressing overlapping 
gene fragments as trpE-gD fusion protein and by syn- 
thetic peptide mapping. In addition, the BHV-5 gD se- 
quence was determined and analyzed by comparison 
with the BHV-1 gD sequence. BHV-1 gD-specific MAbs 
were reacted first with trpE-gD fusion proteins to local- 
ize the sites to regions in the glycoprotein. Precise sites 
then were predicted by analyzing differences, in the pre- 
dicted amino acid sequences and antigenicity and hydro- 
pathicity plots, of BHV-1 and BHV-5 gD regions that likely 
corresponded to epitopes (BHV-1) and lack of epitopes 
(BHV-5). Finally, synthetic peptides were prepared and 
tested for epitope specificity. 
MATERIALS AND METHODS 
Virus strains and cell lines 
The Oooper (Colorado-I) strain of BHV-1 was obtained 
from the American Type Culture Collection (ATCC; Rock- 
ville, MD). The TX-89 strain of BHV-5 (isolated from a case 
0fviral encephalitis (d'Offay eta/., 1993) was provided 
by Dr. d'Offay from Oklahoma State University. The two 
viruses were propagated and titrated in Madin-Darby 
bovine kidney (MDBK) cells grown in Dulbecco's modi- 
fied Eagle's medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS). 
M0noclonal antibodies 
MAbs 3402 and R54 are both gD-specific (Marshall et 
aL, 1986; Chowdhury, unpublished data); however, MAb 
R54 was previously characterized to be gC-specific (Tre- 
panieretaL, 1986; Abdelmagid etaL, 1992) and has now 
been reevaluated in our laboratory to have gD specificity. 
MAb 3402 was provided by Dr. G. Letchworth from the 
University of Wisconsin at Madison. 
SDS-PAGE and Western blot analysis 
Sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis (SDS-PAGE) of viral or bacterially expressed 
fusion proteins was performed under reducing condi- 
tions as described earlier (Laemmili, 1970; Yei et aL, 
1990). Following electrophoresis, proteins were trans- 
ferred electrophoretically to nitrocellulose (NO) mem- 
branes. NC membranes were blocked in 3% nonfat milk 
in TBS (20 mM Tris-HCI, pH 7.5, 0.5 M NaCI) or PBS 
and then reacted overnight with MAbs, rabbit, or bovine 
antisera diluted in TBS or PBS containing 1% gelatin. 
After being washed with TBS or PBS containing 0.05% 
Tween 20, blots were reacted with biotinylated second- 
ary antibodies for 1 to 2 hr at room temperature (RT), 
followed by incubation for 30 min at RT with avidin- 
peroxidase complex (VectaStain; Vector Laboratories). 
Bound antibody was visualized by development in horse- 
radish peroxide substrate solution according to the man- 
ufacturer's protocol (Pierce Biochemical). 
Construction of recombinant pATH expression 
plasmids and preparation of fusion proteins 
The 1.3-kb Mael/Mael fragment containing the whole 
BHV-1 gD ORF (Tikoo et al., 1990) was blunt ended 
(Klenow) and cloned into the Smal site of a pATH 23 
plasmid (Koerner et aL, 1991) to yield the inframe trpE- 
gD fusion gene (plasmid clone pgD1-417). The recombi- 
nant plasmid was used to transform Escherichia coli Re- 
print requests cells, and insert-containing transformants 
were selected by colony hybridization using 32p-nick- 
translated-specific probes, A clone containing the gD 
coding sequences in the correct orientation (verified by 
sequencing) was selected and tested for gD expression 
(described below). All subsequent clonings spanning 
portions of the gD OBF were generated either directly or 
indirectly from this clone. 
Construction ofpgDl-216. Plasmid pgD1-417 was di- 
gested with Xbal and Sinai. The 746-bp fragment was gel 
purified and inserted into Xbal/Smal-digested pATH23 
plasmid. 
Construction of pgDl-164. Plasmid pgD1-216 was di- 
gested with Narl and treated with the Klenow enzyme. 
The DNA was redigested with Smal and the larger frag- 
ment was purified and religated. 
Construction of pgD1-49. Plasmid pgd1-164 was di- 
gested with Apal and Sacl and blunt end repaired with 
T4 DNA polymerase and the large fragment was purified 
and religated. 
Construction ofpgD52-164. Plasmid pgD1-164 was di- 
gested with Apal and blunt end repaired with T4 DNA 
polymerase. The DNA was redigested with Sacl and the 
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smaller fragment (350 bp) was purified and inserted into 
Smal/Sacl-digested pATH23 plasmid. 
Construction of pgD129-216. Plasmid pgD1-216 was 
digested with Banll and blunt end repaired with T4 DNA 
polymerase. The 280-bp fragment was purified and in- 
serted into Smal-digested pATH 23 plasmid (in right ori- 
entation). 
Construction of pgD117-164. Plasmid pgD1-164 was 
digested with Sphl, blunt end repaired with T4 polymer- 
ase, and then digested with Xmalll and treated with the 
Klenow enzyme, The large fragment was purified and 
religated. 
Construction of pgD165-216. Plasmid pgD1-216 was 
digested with Sphl and blunt end repaired with T4 poly- 
merase. The DNA was redigested with Narl and treated 
with the Klenow enzyme, and the large fragment was 
purified and religated. 
Construction of pgD52-126. Plasmid pgD52-164 was 
digested with Banll and blunt end repaired with T4 DNA 
polymerase. The large fragment was purified and reli- 
gated. 
The synthesis of trpE-gD fusion proteins was induced 
in modified M9 medium by tryptophan starvation and 
indoleacrylic acid (IAA) as described (Koerner et aL, 
1991). Briefly, modified M9 medium containing 0.5% ca- 
samino acids, 50 #g/ml ampicillin, and 20 #g/ml trypto- 
phan was inoculated with transformed E. coil RRI cells 
and grown to midlogarithmic phase. The fusion protein 
was induced in a 1=10 dilution of this culture in modified 
M9 medium without tryptophan and by addition of IAA 
(10 #g/ml). After an additional 4 hr of growth, cell lysates 
of E. coil producing either trpE or the trpE-gD recombi- 
nant proteins were prepared by centrifugation and ho- 
mogenization of the cell in lysis buffer (0.05 M Tris- 
HCI, pH 7.5, 3 mg/ml lysozyme, 0.7% Nonidet P-40) and 
analyzed in a 10% SDS-PAGE gel. 
Preparation of trpE-gD fusion proteins for 
immunization 
A trpE-gD fusion protein antigen was prepared by 
elution from an NO membrane (Szewczyk and Summers, 
1988). Briefly, after preparative electrophoresis and 
transfer of the protein to the NO membrane, the mem- 
brane was washed in PBS containing 0.1% Tween 20 to 
remove SDS and then air-dried. The portion containing 
the trpE-gD fusion protein was sliced, dissolved in di- 
methyl sulfoxide (DMSO), and precipitated by adding an 
equal volume of 0.05 M sodium carbonate buffer, pH 9.6, 
and centrifuging. The pellet was resuspended in PBS, 
emulsified in Freund's complete adjuvant, and used for 
immunization. 
Mapping, cloning, and sequencing of the BHV-5 gD 
gene 
The location of the BHV-5 gD gene on the virus ge- 
• nome and pertinent restriction sites for subcloning and 
the sequencing strategy are illustrated in Fig. 1. A pUC- 
based plasmid library containing the BamHI genomic 
fragments of the BHV-5 genomic DNA was developed. 
To verify the general location of the BHV-5 gD gene, 
the 1.3-kb MaeI-Mael subfragment subcloned from the 
Hindlll K fragment (Mayfield et aL, 1983) carrying the 
gD of BHV-1 was labeled with 32p by nick-translation 
(Sambrook eta/., 1989) and used as a probe for hybridiza- 
tion (Chowdhury et al., 1990) with the 14.6-kb BamHI C 
fragment of BHV-5 (Engles et al., 1987; Bulach and Stud- 
dert, 1990). To precisely map the location of the BHV-5 
gD gene, the BamHl-C fragment was digested further 
with restriction endonucleases, separated on agarose 
gel, and analyzed by hybridization with the same probe. 
Based on the hybridization results, a 1.62-kb Mael frag- 
ment (MU 0.886-0.899) was identified and cloned. A re- 
striction map of the cloned 1.62-kb fragment was con- 
structed, and .subclones spanning the entire fragment 
were generated. DNA was sequenced by using both the 
chemical method (Maxam and Gilbert, 1977) and the di- 
deoxy chain termination method (Sanger et al., 1977). 
Both strands of each fragment were sequenced by Sang- 
er's method and verified by Maxam and Gilbert's method. 
Sequence analysis 
DNA sequence data were assembled and analyzed 
using the Seqaid II sequence analysis software (D. D. 
Rhodes and D. J. Roufa, Center for Basic Cancer Re- 
search, Kansas State University (KSU), Manhattan). The 
predicted amino acid sequences of BHV-5 (this study) 
and BHV-1 gD (Tikoo et al., 1990) were aligned by using 
Multalin software (Corpet, 1988). Hydropathicity analyses 
were performed (Kyte and Doolittle, 1982) using a g- 
amino-acid Window, and the antigenicity profiles of pre- 
dicted amino acid sequences were analyzed using the 
Seqaid II software. 
Peptide synthesis 
Peptides were synthesized at the Biotechnology Cen- 
ter of KSU by FMOC chemistry (Barany and Merrifield, 
1980) on an ABI Model 431A automated peptide synthe- 
sizer (Applied Biosystem, Inc., Foster City, CA) according 
to the manufacturer's protocols. The peptides correspond 
to the BHV-1 gD protein's predicted aa residues 92-106, 
202-225,202-213, and 2t3-225. The peptides were pu- 
rified by high performance liquid chromatography. To fa- 
cilitate conjugation to keyhole limpet hemocyanin (KLH), 
an additional irrelevant cysteine was added at the C- 
terminus of peptide 92-106. Peptides 92-106 and 202- 
213 were conjugated to KLH using succinimidyl 4-(N- 
maleimidomethyl-cyclohexane)-l-carboxylate as a cross 
linker. 
Immunization of rabbits 
New Zealand white rabbits were injected intradermalty 
at multiple sites along the back and subcutaneously at 
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FIG. 1. The BamHI restriction site map of BHV-5 DNA and the cloning and sequencing strategies of BHV-5 gD gene. The genomic organization 
of BHV-5 (TX89) strain, depicted on top, consists of unique long (UL) and short (Us) regions and two repeat regions (IR and TR). The BamHI restriction 
endonuclease map was described originally for the (N569) strain of BHV-5 by Engles et al. (1987). The gD gene of BHV-5 was mapped to the 
BamHl-C (14.6 kb) genomic fragment between MU 0.827 and 0.944 and then to the Mael fragment (1620 bp) between MU 0.886 and 0.899 by 
subcloning and hybridization with radiolabeled BHV-1 gD gene DNA probe. A restriction site map of the Mael (1620 bp) fragment was generated, 
and various restriction endonuclease subfragments, indicated as bold lines, were cloned and sequenced. The arrow represents the BHV-5 gD QRF, 
which is 1251 nucleotides long, starting with the ATG codon and terminating with TGA. The arrowhead shows the direction of transcription. 
the inguinal region with a total of 300 fig conjugated 
synthetic peptides or trpE-gD fusion protein emulsified 
in Freund's complete adjuvant. Second and third injec- 
tions were given intramuscularly at biweekly intervals in 
incomplete Freund's adjuvant. Rabbits were bled 1 week 
after each booster dose and sera were analyzed for spe- 
cific antibodies by Western blot and slot blot ELISA 
against the corresponding antigen and by virus neutral- 
ization. 
Slot blot ELISA 
Slot blot ELISA was performed using a microsample 
blotting apparatus (ABN, Hayward, CA). Each slot was 
coated with 40 or 8 #g of peptides dissolved in 0.05 M 
sodium carbonate buffer (pH 9.6) or borate buffer (0.01 
sodium borate, 0.15 M NaOl, pH 8) or virus protein 
and dried at room temperature. The large amount of pep- 
tide per slot was necessary because the binding of these 
peptides to NO membranes was relatively weak. 
Amounts of bound protein were determined by Ponceau 
S protein staining (Sigma, St. Louis, MO). The immu- 
n0blotting assay was carried out as described earlier. 
Neutral ization assay  
The neutralization assay was performed essentially as 
described by Chowdhury et al., (1988). Briefly, rabbit sera 
(inactivated by 56° for 30 min) or MAb ascites fluids were 
diluted in DMEM containing 5% FBS and incubated with 
50-100 PFU of virus for 1 hr at 37 °. Antibody-virus mix- 
tures were added to confluent MDBK monolayers in 24- 
well plates, allowed to adsorb for 1 hr, and overlaid with 
1.2% methylcellulose in DMEM containing 2% FBS. After 
2 -3  days of incubation, cells were fixed with 10% formal- 
dehyde and stained with 0.35% crystal violet; then 
plaques were counted. Titers were expressed as recipro- 
cals of the highest dilutions that reduced plaques by 50%. 
In vitro neutralization inhibition assay  
Serial fivefold dilutions of peptides (in DMEM), starting 
at a concentration of 25 #g/ml, were incubated with an 
equal volume of MAb or bovine convalescent serum dilu- 
tion that gave 50% plaque neutralization and then allowed 
to react for 1.5 hr at 37 ° . BHV-1 was added to yield an 
effective dose of 100 PFU/200 ffl of the mixture and incu- 
bated for an additional 1 hr at 37 °. Two hundred microli- 
ters of the mixture was added to each of two wells of 
confluent MDBK monolayer in a 24-well plate, and the 
neutralization assay was continued as described above. 
As controls for the assay, virus was incubated with pep- 
tide alone or antibody (Ab) alone. The ability of each 
peptide to inhibit the neutralizing activity of the corre- 
sponding antibody was calculated by the formula 
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FIG. 2. SDS-PAGE and immunoblotting analysis of trpE-gD fusion proteins. Coomassie blue-stained gel showing fusion proteins expressed by 
subfragments of gD ORF using the pATH vector system (A) and immunoreactivity of the same proteins with MAb R54 (B) and 3402 (C). Lane 1, 
trpE; Lane 2, trpE-gD (1-417); lane 3, trpE-gD (1-216); lane 4, trpE-gD (1-164); lane 5, trpE-gD (52-164); lane 6, trpE-gD (52-126); lane 7, 
trpE-gD (1-49); lane 8, trpE gD (129-216); lane 9, trpE-gD(t17-164);and lane 10, trpE-gD(165-216). 
Average No. of plaques (peptide and Ab) 
- Average No. of plaques (Ab only) 
X 100. 
Average No. of plaques (peptide only) 
- Average No. of plaques (Ab only) 
Results were recorded and represented as % virus 
plaques restored. 
RESULTS 
Use of recombinant fusion proteins and monoclonal 
antibodies to define epitope structure on the BHV-1 
gD glycoprotein 
The 37-kDa trpE protein (vector control) and the larger 
sized trpE-gD fusion proteins, which were composed of 
the trpE gene plus the gD coding regions of variable length, 
are shown in Fig. 2A. The results of immunoblotting with 
BHV-l-specific gD MAbs R54 and 3402 are shown in Figs. 
2B and 20, respectively. The induced fusion proteins were 
synthesized as single stable poiypeptides, except for the 
fusion proteins containing the whole gD and the N-terminal 
half of gD, which showed an additional band(s) detected 
as a breakdown product of the trpE-gD fusion protein 
(lanes 2 and 3, respectively, Fig. 2C). The fragment con- 
taining the epitope-bearing sequences in the correct read- 
ing frame was recognized by the MAbs, thus localizing 
the epitope region in the glycoprotein. A summary of the 
reactivity of the fusion proteins with these MAbs and the 
restriction endonuclease subfragments of the BHV-1 gD 
ORF specifying these proteins is shown in Fig. 3. trpE-gD 
fusion plasmids expressing the aa residues 1-417 (entire 
gD ORF) and the N-terminal half (aa 1-216) reacted on 
Western blot with both MAbs 3402 and R54. TrpE-gD re- 
combinant plasmids expressing aa residues 129-216 and 
aa residues 165-216 were recognized by MAb R54 but not 
by MAb 3402, narrowing the location of R54 epitope to a 
stretch of 52 amino acids expressed by NarI-Smal subfrag- 
ment (Fig. 3). MAb 3402 recognized overlapping trpE-gD- 
fusion proteins containing gD aa residues 52-164 and aa 
residues 52-126 but did not react with gD aa residues 
117-164, indicating that the location of this epitope is be- 
tween aa residue 52-116, contained in the recombinant 
plasmid expressing the ApaI-Banll subfragment (Fig. 3), 
Immunogenicity of gD fusion proteins 
To determine the immunogenicity of the trpE-gD fu- 
sion protein that expressed the N-terminal 216 amino 
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FIG. 3. Schematic representation of the BHV-1 gD glycoprotein and 
its segments that were xpressed in pATH vectors. The Mael fragment 
containing the gD ORF is depicted on top, showing restriction endonu- 
clease sites used for cloning into pATH plasmids. Glycoprotein Dpr0- 
tein segments expressed are shown as solid bars identified by aa 
numbers on top. The aa indicate restriction sites on the gD QRF. A 
summary of the immunoreactivity of gD protein segments with MAb 
R54 and 3402 is shown on the table to the right, with (+) to denote 
reactivity and (-) for no reactivity. 
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FIG. 4. Immunogenicity ofTrpE-gD fusion protein expressing the N- 
terminal 216 amino acids. (A) The immuneblot reactivity of anti-trpE- 
gD (1-216) rabbit sera with trpE protein alone (lane 1), trpE-gD (1 - 
216) protein (lane 2), BHV-l-infected cells (lane 3), and mock-infected 
cells (lane 4). The locations of gD (lane 3) and trpE-gD (lane 2) fusion 
proteins are indicated by arrows. (B) The immunoblot reactivity of bo- 
vine eera against rpE-gD fusion protein. BHV-l-nonneutralizing (lane 
1)and neutralizing (lanes 2, 3, and 4) bovine sera. A control MAb 3402 
is shown in lane 5. 
acids of BHV-1 gD (subfragment Mael-Smal), rabbits 
were immunized, and BHV-l-neutralizing bovine sera 
were analyzed. The rabbit serum recognized the authen- 
tic BHV-1 gD from BHV-l-infected cells (Fig. 4A), but did 
not neutralize the virus. Bovine sera that had BHV-1- 
specific neutralizing antibodies reacted with the trpE- 
gD (1-216) fusion protein (Fig. 4B). 
Analysis of BHV-5 gD ORF and comparison of 
predicted aa sequences of BHV-5 and BHV-1 gD 
The nucleotide sequence of the BHV-5 gD gene has 
been submitted to the GenBank Databank with the Ac- 
0ession No. U14656. The nucleotide sequence analysis 
of the 1.62-kb Mael fragment (MU 0.886-0.899) coding 
the gD gene identified only one 1251-bp ORF (from nt 
247to nt 1497) coding for 417 aa residues (Fig. 5), large 
enough to encode the BHV-5 gD gene. Hydropathic anal- 
ysis of the predicted protein revealed the presence of 
two prominent hydrophobic peaks similar to the BHV-1 
gD, representing the signal sequence and the transmem- 
brane anchor sequence (Fig. 6). Based on empirical rules 
f0rpredicting signal sequences (von Heinje, 1986), amino 
acid residues 4 to 18 have the position, length, relative 
hydrophobicity, and consensus cleavage site character- 
istic of a signal sequence. Similarly, amino acid residues 
356 to 382 have the position, length, and relative hydro- 
phobicity characteristic of a transmembrane anchor se- 
quence (Figs. 5 and 6). 
Alignment of the predicted aa sequences of the BHV- 
5 gD gene with the corresponding sequences of BHV-1 
(Tikoo et al., 1990) showed that the amino terminal two- 
thirds of the protein (1-282 of BHV-5 gD) is relatively 
well conserved; however, the carboxy terminal region 
(amino acids 283-354) of BHV-5 gD differs. This region 
is located immediately upstream of the putative trans- 
membrane domain (355-382 of BHV-5 gD) and charac- 
terizes a major hydrophilic peak in the case of BHV-1. In 
the BHV-5, several differences corresponding to the BHV- 
1 sequences resulted in a series of hydrophilic peaks 
compared to one broad peak for BHV-1 gD (Fig. 6). A 
series of negatively charged residues from amino acids 
281 to 295 (residue 280-292 of BHV-1) (Tikoo eta/., 1990) 
are present in this segment of the BHV-5 gD, which exhib- 
its several mismatches with respect to the BHV-1 se- 
quence. As in other alphaherpesvirus gD homologues, 
the predicted protein has seven cysteine residues, six of 
which are located in the putative external domain. All 
cysteine residues are conserved between the two se- 
quences and two potential N-linked glycosylation sites 
(Kornfeld and Kornfeld, 1985)located at amino acid posi- 
tions 102 and 411 of BHV-1 gD are conserved, but a third 
site at amino acid position 41 of BHV-1 gD is missing in 
the BHV-5 gD (Fig. 5). 
Alignment of BHV-5 gD sequences corresponding to 
epitope bearing sites of BHV-1 gD show differences 
We compared the BHV-5 gD sequences corresponding 
to the BHV-1 epitope coding regions, defined above us- 
ing recombinant fusion proteins, to map the epitope-cod- 
ing sequences specified by MAbs 3402 and R54 pre- 
cisely. Specific changes in the predicted amino acid se- 
quence and their effect on the hydrophilic (data not 
shown) and potential antigenic properties (Fig. 7) were 
analyzed. Because the two MAbs recognize only BHV-1 
gD and not BHV-5 (type specific), these epitopes should 
be in the regions of BHV-1 gD that correspond to the 
altered amino acids on BHV-5 gD. Antigenicity plot analy- 
sis (Fig. 7A) of amino acid sequence 52-115 indicated 
some potential antigenic regions. A comparison of the 
amino acid sequences of these regions with the corre- 
sponding regions of BHV-5 gD showed that five amino 
acids were different. Four of the five mismatches are 
clustered in one region at positions 92, 97, 98, and 100, 
and one amino acid change occurred at position 57 of 
BHV-1 gD. An antigenic peak between residues 94 and 
101 of BHV-1 gD was lost on the corresponding region 
of BHV-5 gD (Fig. 7A), probably because of the four amino 
acid mismatches. Based on these observations, a 12- 
mer peptide covering residues 92-106 was synthesized 
and analyzed further. 
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1 . . . . . . . . . . . . . . .  +++ 59 
BHV- I .gD -MQGPTLAVLGALLAVAVS~PTPAPRVTVYVDPPAYPMPRYNYTERWHTTGPIPSPFADG 
: : : : : : : :  : : : : : : : : : : : : : : : : : : :  : : : : :  : : : : : : : : : : : : :  :: 
BHV-5 .gD MRRLALLSVLGALLAAAAGLPTPAPRVTVYVDPPAYPPPRYNYIERWHTTGPIPSPFQDG 
1 . . . . . . . . . . . . .  60  
+++ 119 
BHV- I .gD REQPVEVRYATS~MLAL IADPQVGRTLWEAVRRHARAYNATVIWYKIES . .~:~RPLY  
. . . . . . . . . . . . . . . .  ::: . . . . .  : : : : : : :  : : : :  : : : : : : : : : : : : : : : : : : : :  
B.v-sgD Ii6    i i ; . Lii; QVG TLWGAV ERTY"ATVlWYKIES    Y 
* +++ 120 
179 
BHV- I .gD YMEYT:E~EPRKHFG:~:YRTPPFWDSFLAGFAYPTDDELGL IMAAPARLVEGQYRRALY I  
. . . . . . . .  ::: : : : : : : : : :  : : : : : : : : : : : : : : :  : : : : : : :  : : : : : : : : : :  
BHV-5 .gD YMEYS~PKKf iFGY~RYRTppFWDGFLAGFAYPTDDELGLVMAAPARLAEGQYRRALY I  
, . * 180  
239 
BHV- I .gD DGTVAYTDFMVSLPAG:~:FSKLGAARGYTFG:~:PARDYEQKKVLRLTYLTQYYPQEAH 
. . . . . . . . .  . . . ,  . . . . . . . . . . . . . . . . .  • . . . . . . . . .  • . . . . . . . . . . . .  
, 240  
297 
BHV- I .gD KA IVDYWFMRHGGVVPPYFEESKGYEPPPAADGGSPAPPGDD- -EAREDEGETEDGAAGR 
: : : : : : : : : : :  : : : : : : : : : : : : : : : : : :  : : : : : : :$ :  :: : : : : :  : 
BHV-5 .gD KA IVDYWFMRHEGVVPPYFEESKGYEPPPAVEGASPAPPGDDDGEAHGEGGGEEDGAGGQ 
* * * 300 
357 
BHV- I .gD EGNGGPPGPEGDGESQTPEANGGAEGEPKPGPSPDADRPEGWPSLEAITHPPPAPATPAA 
: : :: : : : : :: : : : : : : : : : : : : : :  ::: : : : : :  
BHV-5 .gD ETGGEGEGPAAAGPDGAPP- -GEPRPGP-GGPGADVDRPEGWPSLEAITRPPPTPATPAP 
* 357  
+++ 417 
BHV- I .gD PDAVPVSVGIGI~I:~:~GAYFVYTRRRGAGPLPRNPKKLPAFGNVNYSALPG 
BHV-5 .gD PTALPVGIGVGIAAAVIA~VAAAGAAAYFVYTRRLGAGPLPKKAKKLLAFGNVNYSALPG 
, . * +++ 417 
FIG. 5. Comparison of the predicted amino acid sequence of the BHV-5 gD with the predicted amino acid sequences of BHV-1 gD (Tikoo et a/., 
1990). The predicted amino acid sequences of the BHV-1 and BHV-5 gD glycoproteins were aligned by using Multalin so~ware (Corpet, 1988). 
Amino acid numbering sta~s at the first methionine, and numbers are shown to the right, Amino acids aligned identically between the two se- 
quences are indicated by two dots, consewative substitutions are marked by an asterisk (*), and conse~ed cysteine residues are boxed. Potential 
N-linked glycosylation sites are indicated (+ + +). The presumptive signal sequences and the transmembrane anchor sequences are shown by 
broken and solid lines, respectively. The position of BHV-1 gD signal peptide cleavage site between amino acids 18 and 19 (Tikoo et al., 1990)is 
marked ($). 
Antigenicity plot analysis of aa residues 165-216 and 
comparison and analysis with the corresponding regions 
of BHV-5 gD showed a total of five amino acid mis- 
matches. Two of these (at positions 205 and 216) affected 
the antigenicity relative to the significant antigenic peaks 
on BHV-1 gD (Fig. 7B). Two additional amino acid mis- 
matches (at positions 217 and 222) could affect the anti- 
genicity of the protein. Based on these observations, 
three synthetic peptides covering amino acids 202-226, 
202-213, and 213-225 were made and analyzed for epi- 
tope activity by neutralization inhibition of MAbs. 
Specificity of synthetic peptides in defining the 
epitopes (MAbs 3402 and R54) 
Peptides 202-225 (data not shown) and 202-213 (Fig. 
8) both showed specificity for MAb R54 but peptides 
213-225 did not show specificity for MAb R54 (Fig. 8), 
and peptides 92-106 showed specificity for MAb 3402 
(Fig. 8). At the 25 #g/ml peptide concentration (optimum 
concentration) and MAb concentration sufficient to re- 
duce 50% of the plaques of the challenge dose (100 PFU), 
the highest percentage (65-68%) of the virus plaques 
was restored (Fig. 8). When peptide 202-213 (specific 
for MAbR54) was tested for the ability to block the BHV- 
1-neutralizing capacity of MAb 3402, it failed to show any 
blocking effect (data not shown). Thus, the blocking of 
MAb neutralization was a specific interaction of peptide 
and MAb and not due to inactivation of irrelevant anti- 
body by these peptides. To determine if any of the virus- 
neutralizing activity in bovine convalescent serum is 
against the epitopes recognized by the MAbs, similar 
experiments, using bovine serum and peptides (202-213 
and 92-106), were performed. The results revealed only 
20-25% (highest) virus plaques restoration at the 25 #g/ 
ml peptide concentration (data not shown). 
Two peptides, 92-106 and 202-213, were injected 
into rabbits for further evaluation. Antisera from these 
rabbits were tested for peptide and viral antigen specific- 
ity by slot blot ELISA and virus neutralization. Each anti- 
peptide serum reacted specifically to the immunizing 
peptide; however, the reactivity of both of the sera with 
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FiG. 6. Comparison of the hydropathicity plots of the amino acid 
sequences of BHV-1 and BHV-5 glycoproteins D. The BHV-5 and BHV- 
1 gD amino acid sequences were analyzed for hydropathicity character- 
istios (Kyte and Doolittle, 1982) using a 9-amino-acid window. The BHV- 
5gD is shown on top, and the BHV-1 gD (Tikoo etaL, 1990) is shown 
on the bottom of the figure. The hydropathic scores and the amino acid 
numbers are shown on the vertical and horizontal axes, respectively. 
the virus antigen was stronger (Fig. 9A). On Western 
blots, both the antipeptide (92-106 and 202-213) sera 
recognized strongly a 30K protein band from BHV-I-in- 
fected MDBK cell lysate (Fig. 9B). A control MAb R54 
(Fig, 9B, lane 5) reacted with the whole gD and the 30K 
bands. No reaction was detected by antipeptide sera 
against mock-infected MDBK cells. In the plaque reduc- 
tion assay, both of the antipeptide sera showed low neu- 
tralizing activity (titer 1,4) against BHV-1. 
DISCUSSION 
Several approaches have been used to identify anti- 
genic sites on BHV-1 glycoprotein D, including competi- 
tion binding assays (Marshall eta/., 1988; Hughes eta/., 
1988; van Drunen Little-van den Hurk et aL, 1984) and 
expression of mutant forms of the protein in a mammalian 
expression system (Tikoo et al., 1993). Although the latter 
approach has mapped epitopes within amino acid re- 
gions 164-216 and 320-355, the precise amino acid 
sequences of these epitopes were not identified. The 
main purpose of this study was to identify the precise 
location and amino acid sequences of linear antigenic 
determinants of BHV-1 gD that reacted with neutralizing 
BHV-1 gD-specific MAbs (MAbs 3402 and R54). To 
achieve this goal, the location of linear antigenic determi- 
nants was identified in segments of the BHV-1 gD ORF 
by expressing genomic subfragments in E. coil and then 
determining their reactivity with the MAbs. Second, anti- 
genic and hydrophilic properties of the predicted amino 
acids encoded by the epitope-bearing fragments were 
analyzed and compared with the corresponding regions 
of the BHV-5 gD sequence (BHV-5 is resistant o neutral- 
ization by MAbs 3402 and R54). Third, specific differ- 
ences in the predicted amino acid sequences that likely 
corresponded to recognition or lack of recognition by 
MAbs 3402 and R54 were identified in the BHV-5 gD 
ORF, and their effects on the antigenicity and hydrophilic- 
ity were determined. Based on these analyses, peptides 
corresponding to BHV-1 aa sequences were synthesized 
and tested for their specificity against MAbs in competi- 
tion neutralization assays with virus. Previous studies 
have located three linear (conformational-independent) 
epitopes (la, Ilia, and IV) on three separate antigenic 
domains of BHV-1 gD protein (Tikoo et aL, 1993; van 
Drunen Little-van den Hurk eta/., 1984, 1990b). The pres- 
ent resul{s showed that neutralizing MAb R54 recognized 
a trpE-gD fusion protein (165-216) specified by restric- 
tion fragment NarI -Smal .  A linear gD epitope specified 
by MAb 9D6, was identified in this region (Tikoo et al., 
1993). Whether this is the same linear epitope should be 
examined directly. Competition with peptides 202-213 
further identified the location by reducing the neutralizing 
activity of MAb R54 in a competition neutralization inhibi- 
tion assay. 
MAb 3402 neutralizes BHV-1 by blocking viral penetra- 
tion into susceptible cells (Dubuisson eta/., 1992). Based 
on competition binding assays, it has been assigned to 
an antigenic site (V) of BHV-1 gD (Marshall et al., 1988). 
We have mapped the 3402 epitope to a linear antigenic 
site between amino acid residues 92 and 106. MAb 3402 
recognized a trpE-gD (aa 52-126) fusion protein speci- 
fied by the ApaI -Ban l l  subfragment of the gD ORF. Anti- 
genic analysis and comparison of region aa 52-115 with 
BHV-5 gD revealed five amino acid mismatches. Four 
were nonconservative amino acid changes (between res- 
idues 94 and 101) and corresponded to an antigenic 
peak on the BHV-1 gD that was absent on BHV-5 gD. A 
synthetic peptide covering region 92-106 reduced the 
neutralizing activity of MAb 3402. 
Both peptides 92-106 (MAb 3402) and 202-213 (MAb 
R54) induced rabbit antisera that showed neutralizing 
activity against BHV-1 and recognized a 30-kDa band 
(probably a breakdown product of gD) in immunoblots 
containing viral lysates. Similar antipeptide sera reactive 
with lower molecular size bands have been observed for 
gD of the herpes simplex virus (Weijer eta/., 1988). Both 
peptides partially reduced virus neutralization by their 
respective MAbs. Neutralizing activity of MAbs could not 
be inhibited completely, even by increasing the peptide 
concentration (data not shown). The inability of the syn- 
thetic peptides to induce highly neutralizing antibody and 
to completely inhibit virus neutralization by MAbs could 
be explained by variations in "conformationar' properties 
of the peptides with respect to the native protein struc- 
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FIG. 7. Comparison of antigenicity plots of epitope-bearing amino acid regions of BHV-1 gD with the corresponding regions of BHV-5 gD. Antigenic 
analyses of amino acid regions of BHV-1 gD recognized by MAb 3402 (A) and MAb R54 (B) are shown on the bottom, whereas the corresponding 
regions of BHV-5 gD antigenicity analyses are shown on the top of each figure. The antigenicity score and amino acid sequences are shown on 
the vertical and horizontal axes, respectively. Amino acid changes occurred on BHV-5 gD are indicated by arrows. Synthetic peptide sequences 
bearing epitopes for MAb 3402 (92-106) and MAb R54 (202-213) are underlined. 
ture and, thus, reduce antibody binding. Both peptides 
were much less effective in inhibiting virus-neutralizing 
activity of bovine convalescent serum compared to neu- 
tralization by gD-specific MAbs 3402 and R54. This could 
be attributed to a broad range of specificities of neutraliz- 
ing antibodies against other viral glycoprotein epitopes 
(gD as well). 
These epitopes may be important in inducing protec- 
tive immunity against BHV-1 infection for the following 
reasons (i) MAbs specific to these epitopes neutralize 
BHV-1 in the absence of complement (MAb 3402, Dubuis- 
sion eta/., 1992; MAb R54, Chowdhury, unpublished ata) 
and (ii) convalescent sera (with neutralization titers 
against BHV-1) from cattle naturally infected with BHV-1 
reacted to the bacterially expressed N-terminal half (1- 
216) of gD that includes both epitopes. Epitopes on the 
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FiG. 8. Inhibition of monoclonal antibody neutralization by peptides. 
FJvefold dilutions of peptides starting at a concentration of 25 #g/ml 
of DMEM were incubated with equal volumes of limiting MAb dilution 
lid2,000) and allowed to react for 90 rain at 37 °. BHV-1 was added to 
a final number of 100 PFU/200 #1 of the mixture and incubated for an 
additional 1 hr, and the neutralization assay was continued as e- 
scribed under Materials and Methods. The ability of each peptide to 
reduce the neutralizing activity of MAb was recorded as % virus plaques 
restored. Each bar represents an average of four readings. The legends 
are shown on the upper right of the figure. 
BHV-1 gD molecule bound by MAbs 3402 and R54 may 
be critical to the functional interaction of the virus with 
cell membrane and membrane-bound molecules as well 
as being a target for the protective immunity in cattle. 
Further studies are required to determine the functions 
of these epitopes in v i rus-ce l l  interactions. 
Rabbit antisera against trpE-fusion protein expressing 
the N-terminal half (1-216) of gD recognized gD mole- 
cules from infected cell lysate, but did not neutralize the 
virus. An E. co~i-expressed BHV-1 gD protein has been 
shown to elicit a low neutralizing antibody response in 
cattle. This was attributed to the lack of glycosylation 
and to conformational changes of discontinuous epi- 
topes caused by poor dimerization (van Drunen Little- 
van den Hurk eta/., 1993). In our studythe failure of rabbit 
antibody to neutralize BHV-1 could not be explained by 
conformational dependence since the fusion protein (1-  
216) contained at least two conformation- independent 
neutralizing epitopes. An important N-linked glycosyla- 
tion site has been reported within this region (aa residue 
102) (Tikoo et al., 1993). However, as evidenced by the 
reactivity of MAb 3402 with the fusion protein (aa 52-  
126), the unglycosylated protein appeared to have no 
effect! on the structural conformation of the epitope. 
Our study also showed that, in addition to the differ- 
ences in the two epitope-coding regions, other sequence 
differences occur between BHV-1 and BHV-6 gD genes. 
The C-terminal amino acids (residue 283-354), immedi- 
ately upstream of the putative transmembrane domain, 
showed several differences between the two gD. These 
amino acids are in the major hydrophil ic peak of gD and 
may be important for prote in-prote in interactions (Tikoo 
et aL, 1993). These differences could contribute to biolog- 
ical properties of BHV-5, including the neuroinvasiveness 
of BHV-5. Pro l ine-a lan ine repeats have been described 
in approximately the same region of PRV gD (Petrovskis 
etaL, 1986). This region of BHV-5 gD needs to be further 
characterized. Future studies of BHV-1 and 5 gD should 
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FIG. 9. Immunoreactivity of antipeptide rabbit sera with peptides and BHV-1 proteins. Antipeptide (92-106) and (202-213) rabbit sera were tested 
for BHV-1 and peptide specificities by slot blot ELISA (A). Each antipeptide serum reacted specifically with its immunizing peptide and with the 
virus. The slots were coated with 40 #g (lane 1) and 8 #g (lane 2) of peptide or purified virus protein, and the bound proteins were determined by 
Ponceau S protein staining (Sigma). The antipeptide sera also were tested by Western blot (B) against BHV-l-infected MDBK cells, lane 1 (anti- 
peptide 202-213) and lane 3 (antipeptide 92-106), and against mock-infected ceils, lane 2 (antipeptide 202-213) and lane 4 (antipeptide 202- 
213). Positive control reaction of MAb R54 against BHV-l-infected cells is shown in lane 5. The positions of whole gD and the 30-kDa protein bands 
are marked (*-). 
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determine the mechanism of gD-mediated resistance of 
cells to BHV superinfection and its role in infectivity, im- 
munity, and neuropathogenesis. 
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